- Trial Phase
- Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- Time to Market
- Already approved and marketed — U.S. approval since July 13, 2017 (plaque psoriasis); newest indication (Crohn's disease) approved May 28, 2026.
- Why 4/10
- No hard, dated binary remains for TREMFYA in the next ~12 months: the two big regulatory decisions already landed (FDA supplemental efficacy approvals Sept 26, 2025 for ulcerative colitis and May 28, 2026 for Crohn's disease per BLA 761061 records), so this is an approved, commercializing franchise inside a mega-cap — score 4 in the approved-drug band, and even headline events historically moved JNJ little (the 2017 approval moved the stock ~+0.3% in one day per local catalyst-outcome records).
TREMFYA is J&J's key immunology growth engine (Q2 2026 sales +72.5% YoY per J&J's earnings analysis), but the bull/bear is now about commercial ramp and IBD share gains vs. AbbVie's Skyrizi, not a binary event. Watch the pending Phase 3 pediatric juvenile psoriatic arthritis readout (NCT05083182, trial completed June 2026, results not yet posted), quarterly TREMFYA sales, and any payer/formulary headlines in UC/Crohn's.
Price Chart
Executive Summary
TREMFYA (guselkumab) is Johnson & Johnson's injectable IL-23 blocker, first approved in 2017 for plaque psoriasis and since expanded to psoriatic arthritis, ulcerative colitis (FDA supplemental approval Sept 26, 2025) and Crohn's disease (FDA supplemental approval May 28, 2026), per FDA BLA 761061 records. It is one of J&J's fastest-growing products: J&J's Q2 2026 earnings analysis cites TREMFYA sales up ~72.5% year over year, and royalty holder Royalty Pharma credits Tremfya among drivers of ~14% royalty-receipts growth in Q2 2026. Because the big regulatory binaries have already passed, TREMFYA is now a commercial-growth story inside a ~$600B mega-cap: bullish for the franchise, but with no single near-term event likely to move JNJ sharply (the 2017 approval itself moved the stock only ~+0.3% in a day per local records).
How It Works
TREMFYA is a biologic — a lab-made antibody given by injection — that binds to and neutralizes IL-23, a signaling protein that drives chronic inflammation in the skin, joints, and gut. By blocking IL-23, the drug calms the inflammatory pathway behind plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease (FDA classifies it as an Interleukin-23 Antagonist).
Trial Status
FDA records show supplemental efficacy approvals for guselkumab (subcutaneous and IV forms) on Sept 26, 2025 (ulcerative colitis expansion) and May 28, 2026 (Crohn's disease expansion). A Phase 3 study in moderately-to-severely active Crohn's disease (NCT04397263, Janssen) is marked COMPLETED (last updated Feb 2026); a Phase 3 pediatric juvenile psoriatic arthritis study (NCT05083182) completed June 2026 with results not yet posted; a Phase 3 skin-of-color psoriasis study also completed.
The Two-Sided Case
Upcoming Catalysts
- Pending Phase 3 pediatric juvenile psoriatic arthritis readout (NCT05083182 — trial completed June 2026, results not yet posted)
- Quarterly TREMFYA sales disclosures in J&J Q3 2026 earnings (next ~Oct 2026)
- UC/Crohn's commercial uptake and payer/formulary coverage developments
- Potential further pediatric/label-expansion regulatory filings
- Competitive watch: Skyrizi (AbbVie) share gains and Entyvio biosimilar launches in IBD
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report